Epidemiology, biochemistry and some results with treatment of postmenopausal osteoporosis.
The present chapter deals with postmenopausal osteoporosis. This is an important disease because it affects millions of people throughout the world. The most serious of the osteoporotic fractures, the hip fractures, needs hospitalization, causes a high degree of mortality, and results often in dependent people. Osteoporosis is thus a significant socioeconomic burden. At the menopause bone turnover increases and bone loss accelerates. Postmenopausal bone loss and osteoporosis may be prevented by oestrogen replacement therapy, but convincing therapy for established osteoporosis does not yet exist. Anabolic steroid therapy can, however, increase the bone mineral content a few percentages a year in postmenopausal osteoporotic women.
Hassager
C
C
Center for Clinical and Basic Research, Ballerup, Denmark.
Christiansen
C
C
D000368:Aged; D000369:Aged, 80 and over; D045930:Anabolic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D003430:Cross-Sectional Studies; D003718:Denmark / Q000453:epidemiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015994:Incidence; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077603:Nandrolone Decanoate; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology
D045930:Anabolic Agents; D009277:Nandrolone; D000077603:Nandrolone Decanoate